title: [Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
abstract: The incidence of brain metastases from breast cancer is increasing with diagnosis and therapeutics progress, especially with systemic therapies. The occurrence of multiple brain metastases remains a delicate situation when surgery and stereotactic radiosurgery are not indicated, nor available. Treatment strategy is based on the patient's general condition and extracranial disease status. Whole brain radiation therapy remains the gold standard local treatment but its efficacy is limited with a median overall survival of 6 months. New strategies are needed for increasing survival and patients' quality of life. Combining radiation therapy and chemotherapy has been a subject of interest. This article sums up the different radiotherapy plus concomitant systemic therapies combinations for the treatment of brain metastases from breast cancer.
authors.affiliation: Département d'oncologie radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France. Electronic address: cao.kim@hotmail.fr.
authors.forename: K I
authors.initials: KI
authors.lastname: Cao
authors.affiliation: Département d'oncologie radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: Y M
authors.initials: YM
authors.lastname: Kirova
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001812:Blood-Brain Barrier / Q000502:physiology; D001932:Brain Neoplasms / Q000378:metabolism / Q000556:secondary* / Q000628:therapy*; D001943:Breast Neoplasms / Q000473:pathology*; D000069287:Capecitabine; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000077204:Temozolomide; D013792:Thalidomide / Q000627:therapeutic use; D059004:Topoisomerase I Inhibitors / Q000627:therapeutic use; D019772:Topotecan / Q000627:therapeutic use; D000068878:Trastuzumab; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000069287:Capecitabine; D002945:Cisplatin; D003606:Dacarbazine; D003841:Deoxycytidine; D005472:Fluorouracil; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000077204:Temozolomide; D013792:Thalidomide; D059004:Topoisomerase I Inhibitors; D019772:Topotecan; D000068878:Trastuzumab; D014747:Vinblastine; D000077235:Vinorelbine; C508053:ERBB2 protein, human
keywords: Anti-HER2; Anti-HER2 therapy; Brain metastases; Breast cancer; Cancer du sein; Concurrent radiochemotherapy; Métastases cérébrales; Radiochimiothérapie; Radiothérapie encéphalique; Whole brain radiation therapy